An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis

Seminars in Arthritis and Rheumatism
Jean-Pierre RaynauldJean-Pierre Pelletier

Abstract

The aim of the study was to evaluate by quantitative magnetic resonance imaging the effect of celecoxib 200 mg daily on cartilage volume loss over 12 months in knee osteoarthritis. The primary outcome of this study was to evaluate cartilage volume loss in the medial compartment of the knee (femoral condyle and tibial plateau) assessed by quantitative magnetic resonance imaging on subjects receiving continuous treatment with celecoxib 200 mg daily for 12 months compared with a modelized historical control cohort, as expressed by the percentage loss from baseline. Safety of the medication was also assessed. Comparison of the observed volume loss to the expected loss was evaluated by a multivariate linear regression model based on a historical cohort. For the primary outcome, the 95% confidence intervals for the mean observed celecoxib cohort joint medial compartment cartilage volume loss (6.81% [6.01; 7.60]) and mean predicted loss (modelized historical cohort) (5.65% [5.10; 6.19]) overlap, indicating no significant difference and hence no effect of celecoxib on the medial compartment cartilage volume loss. Similar findings were demonstrated for the lateral compartment cartilage loss. The safety data reported several minor advers...Continue Reading

References

Sep 15, 2001·Annals of the Rheumatic Diseases·F M CicuttiniS L Stuckey
Aug 2, 2003·IEEE Transactions on Bio-medical Engineering·Claude KauffmannJacques A de Guise
Sep 11, 2003·Annals of Internal Medicine·David T FelsonDaniel Gale
Dec 1, 1957·Annals of the Rheumatic Diseases·J H KELLGREN, J S LAWRENCE
Dec 1, 1957·Annals of the Rheumatic Diseases·J H KELLGREN, J S LAWRENCE
Dec 3, 2003·Annals of the Rheumatic Diseases·K M JordanUNKNOWN Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT
Feb 14, 2004·Annals of the Rheumatic Diseases·A E WlukaF M Cicuttini
Oct 29, 2005·Arthritis and Rheumatism·Joachim ListingAngela Zink
Nov 1, 2005·Arthritis and Rheumatism·Kenneth D Brandt, Steven A Mazzuca
Feb 28, 2007·Annals of the Rheumatic Diseases·Loreto CarmonaUNKNOWN BIOBADASER and EMECAR Groups
Jan 21, 2009·American Journal of Epidemiology·Mark LuntUNKNOWN British Society for Rheumatology Biologics Register Control Centre Consortium

❮ Previous
Next ❯

Citations

Oct 1, 2011·Arthritis Research & Therapy·Manon C ZweersSimon C Mastbergen
Jan 15, 2013·Rheumatic Diseases Clinics of North America·Ali GuermaziFrank W Roemer
Oct 4, 2014·Osteoarthritis and Cartilage·F EcksteinC G Miller
May 23, 2015·BioMed Research International·Hongsik ChoKaren A Hasty
Feb 16, 2011·Osteoarthritis and Cartilage·D HayashiD J Hunter
Sep 8, 2016·JBJS Reviews·Shaafiya Ashraf, Adnan Zahoor
Aug 12, 2016·Sports Health·Qi LiC Benjamin Ma
Dec 23, 2017·Rheumatology·Zhengping HuangShirley Pei-Chun Yu
Aug 8, 2012·Therapeutic Advances in Musculoskeletal Disease·Yuanyuan WangFlavia M Cicuttini
May 15, 2018·Current Medicinal Chemistry·Miguel D FerrerAntoni Sureda
Oct 12, 2012·Calcified Tissue International·Corinne KlopPaco M J Welsing
Jan 11, 2020·Frontiers in Bioengineering and Biotechnology·Zixuan LinHang Lin
Sep 26, 2020·International Journal of Molecular Sciences·Ufuk Tan TimurPieter J Emans

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.